Volume 4.05 | Feb 12

Hematopoiesis News 4.05 February 12, 2013
Hematopoiesis News

     In this issue: Publications | ReviewsIndustry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
FOXO3A Directs a Protective Autophagy Program in Hematopoietic Stem Cells
Scientists identified autophagy as an essential mechanism protecting hematopoietic stem cells (HSCs) from metabolic stress. They showed that mouse HSCs, in contrast to their short-lived myeloid progeny, robustly induce autophagy after ex vivo cytokine withdrawal and in vivo calorie restriction. [Nature] Abstract

Free Wallchart: Identification Of Colonies Derived From Mouse Hematopoietic Progenitors
PUBLICATIONS (Ranked by impact factor of the journal)


Growth Factor Independence 1 Antagonizes a p53-Induced DNA Damage Response Pathway in Lymphoblastic Leukemia
Since oncogenic signaling activates a p53-dependent DNA damage response and apoptosis, leukemic cells must devise appropriate countermeasures. Researchers showed that growth factor independence 1 (Gfi1) can serve such a function because Gfi1 ablation exacerbates p53 responses and lowers the threshold for p53-induced cell death. [Cancer Cell] Abstract | Press Release

Sustained PU.1 Levels Balance Cell-Cycle Regulators to Prevent Exhaustion of Adult Hematopoietic Stem Cells
To provide a lifelong supply of blood cells, hematopoietic stem cells need to carefully balance both self-renewing cell divisions and quiescence. Although several regulators that control this mechanism have been identified, the authors demonstrated that the transcription factor PU.1 acts upstream of these regulators. [Mol Cell] Abstract

miR-21 Mediates Hematopoietic Suppression in MDS by Activating TGF-β Signaling
Scientists observed that SMAD7, a negative regulator of TGF-β receptor-I kinase, is markedly reduced in myelodysplastic syndromes (MDS), and leads to ineffective hematopoiesis by overactivation of TGF-β signaling. To determine the cause of SMAD7 reduction in MDS, they analyzed the 3’UTR of the gene and determined that it contains a highly conserved putative binding site for microRNA (miR)-21. [Blood] Abstract

Transgene-Free iPSCs Generated from Small Volume Peripheral Blood Non-Mobilized CD34+ Cells
Researchers report a method for deriving induced pluripotent stem cells (iPSCs) from peripheral blood hematopoietic stem cells (HSCs) using immunobead purification and 2-4 day culture to enrich CD34+ HSCs, followed by reprogramming with loxP-flanked polycistronic STEMCCA-loxP lentivector; or with Sendai vectors. [Blood] Abstract

Hematopoietic Stem Cell and Progenitor Cell Mechanisms in Myelodysplastic Syndromes
The authors transplanted purified human hematopoietic stem cells (HSCs) from myelodysplastic syndromes (MDS) samples into immunodeficient mice and show that HSCs are the disease-initiating cells in MDS. [Proc Natl Acad Sci USA] Abstract

Chronic TLR Signaling Impairs the Long-Term Repopulating Potential of Hematopoietic Stem Cells of Wild Type but Not Id1 Deficient Mice
To determine the effects of LPS treatment on hematopoietic stem cell function and to evaluate the significance of Id1 expression, the authors assessed the repopulating potential of wild type and Id1 deficient mice, which were subjected to a 30 day regimen of LPS treatment. [PLoS One] Full Article


Treatment Reduction for Children and Young Adults with Low-Risk Acute Lymphoblastic Leukemia Defined by Minimal Residual Disease (UKALL 2003): A Randomized Controlled Trial
Minimal residual disease (MRD) is the most sensitive and specific predictor of relapse risk in children with acute lymphoblastic leukemia during remission. Researchers assessed whether treatment intensity could be adjusted for children and young adults according to MRD risk stratification. [Lancet Oncol] Abstract

H-Y Antigen-Binding B Cells Develop in Male Recipients of Female Hematopoietic Cells and Associate with Chronic Graft vs. Host Disease
The authors previously showed that IgG allo-antibodies recognize Y chromosome-encoded proteins (H-Y) and a dominant H-Y epitope, DEAD box protein (DBY-2) detectable 6-12 months after transplant in male patients who receive grafts from female donors (F→M) in hematopoietic cell transplantation (HCT). Here they present FACS studies of peripheral blood mononuclear cells collected 6 months after transplant showing that 16 of 28 F→M HCT patients have circulating donor B cells that express B-cell receptor specific for DBY-2. [Proc Natl Acad Sci USA] Abstract | Press Release

Infusion of Megakaryocytic Progenitor Products Generated from Cord Blood Hematopoietic Stem/Progenitor Cells: Results of the Phase I Study
Megakaryocytic progenitor cells (MPs) were produced and characterized from cord blood mononuclear cells under a serum free medium with cytokines. Researchers investigated the feasibility of expansion and infusion of cord blood-derived MPs in 24 patients with advanced hematological malignancies. [PLoS One]
Full Article

Tech Bulletin: Expansion Of Hematopoietic Stem And Progenitor Cells

Wnt Signaling in Normal and Malignant Hematopoiesis
The authors trace the emerging role of Wnt signaling as a critical regulator of distinct aspects of self-renewal and differentiation, its contribution to the maintenance of homeostasis and regeneration, and how the pathway can be hijacked to promote leukemia development. [Cold Spring Harb Perspect Biol] Abstract

Enter Our Contest  
Hematopoiesis News is giving away a free registration for the REGEN 2013 – Clinical Trials & Reimbursement meeting in Boston! Learn to design the optimal clinical trial for your regenerative medicine. Click here to enter.

Regen BioPharma Files Investigational New Drug (IND) Application with FDA on HemaXellerate I™ Stem Cell Drug for Aplastic Anemia
Regen BioPharma, a wholly-owned subsidiary of Bio-Matrix Scientific Group Inc., announced filing of an IND application with the FDA to initiate clinical trials assessing the company’s HemaXellerate I™ stem cell drug in patients with drug-refractory aplastic anemia. [Marketwire] Press Release

Northwestern Medicine Researchers Investigate Stem Cell Therapy for Stroke
Northwestern Medicine® researchers are investigating a novel stem cell therapy, known as SB623, that may hold the key to improving motor function following a disabling stroke. While the study’s primary purpose is to examine the safety of SB623 stem cells, researchers will also seek to determine if the cells are effective in improving stroke symptoms. [Northwestern Memorial Hospital] Press Release

Gamida Cell’s StemEx® Achieves Primary Endpoint in Phase II/III Clinical Study
Gamida Cell announced that its flagship product, StemEx, reached its primary endpoint of improving overall survival in a Phase II/III study which compared the use of StemEx as part of a transplantation regimen to historical controls in the treatment of patients with hematological malignancies such as leukemia and lymphoma. [Gamida Cell] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)
Center for Biologics Evaluation and Research (United States)
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW Clinical Translation of Stem Cells 2013
April 22-23, 2013
Palm Springs, United States

NEW Stem Cells & Cell Therapy Summit
September 5-6, 2013
London, United Kingdom

Visit our events page to see a complete list of events in the hematopoietic community.


Postdoctoral Position – Gene Regulation in the Hematopoietic and Immune Systems (Lund University)

Postdoctoral Positions – Stem Cell Biology (Children’s Hospital Oakland Research Institute)

Postdoctoral Position – Hematopoietic and Malignant Stem Cells (Istanbul University)

Postdoctoral Position – Stem Cell Biology (Washington University of Medicine)

Postdoctoral Research Associate – Stem Cell Biology and Epigenetics (University of Wisconsin)

Postdoctoral Position – Gene Expression and Regulation of Stem Cells (University of Texas at Houston)

Postdoctoral Position – Myeloproliferative Neoplasms (Mount Sinai Medical Center)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us

Suite 201 – 375 West Fifth Avenue
Vancouver, BC V5Y 1J6, Canada